肝胆相照论坛

标题: EDELRIS宣布与ENYO制药独家许可协议 [打印本页]

作者: StephenW 时间: 2015-11-25 16:32 标题: EDELRIS宣布与ENYO制药独家许可协议

本帖最后由 StephenW 于 2015-11-25 16:33 编辑

EDELRIS Announce Exclusive License Agreement with ENYO Pharma

LYON, France, November 24, 2015 /PRNewswire/ --

Edelris announce today that they have out-licensed to Enyo Pharma the patent they co-own with Inserm, Poxel, CNRS, UCBL and ENS-Lyon on a new treatment to cure Hepatitis B.

Hepatitis B virus (HBV) infection is a major public health problem with more than 350 million people chronically infected worldwide, 20 to 40% of them being at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma. Despite the existence of an effective preventive vaccine, the HBV infection is still rampant in many countries, including developed ones, with an estimated 4.5 million new cases of infection per year worldwide. In the frame of the FUI AAP8 founded program NATHEB initiated in 2009 and led by Edelris, with its partners Inserm and Poxel, FXR has been identified as a therapeutic target for HBV and new compounds have been discovered, leading to a strong inhibition of viral HBV DNA and viral antigen production.

"This project demonstrates the ability of Edelris scientists to use their track-proven medchem and molecular modeling expertise to conduct, together with experienced partners at Inserm and Poxel, a successful discovery program. Instrumental to the launch of the project was the contribution of Lyon Biopôle," commented Didier Roche, VP Strategic Innovation of Edelris and former Head of the Natheb project.

"When science and business interests are shared within public-private partnerships, things can move quickly towards valuable results, as has been the case in the Natheb project," added Jean-Yves Ortholand, Edelris' CEO. "We believe Enyo now has the full capability to transform this project into useful therapeutic agents."

Inserm Transfert has been appointed to represent all parties in the patent agreement with Enyo.

Under the license agreement, Edelris is eligible for milestones upon specific development and commercial achievements and would receive royalty payments on sales.

About Edelris

Edelris is a privately-owned research and services company offering original natural product-like collections of screening compounds and innovative fragments for FBDD (Keymical Collections™ and Fragments™), as well as efficient hit/lead optimization capabilities. Since its inception, Edelris has gained many clients worldwide and has successfully developed chemistry programs with major pharmaceutical companies, biotechs and academic groups, either in direct support to their internal discovery efforts or in the framework of collaborative projects.

Contact: Jean-Yves Ortholand
Tél: +33(0)4-37-56-19-03
Email: [email protected]
Web: http://www.edelris.com

SOURCE Edelris

作者: StephenW 时间: 2015-11-25 16:34

EDELRIS宣布与ENYO制药独家许可协议

Google+的
分享LinkedIn

法国里昂，2015年11月24日/新华美通/ -

Edelris今天宣布，他们已经超出授权Enyo医药他们共同拥有同INSERM，Poxel，法国国家科学研究中心，UCBL和ENS-里昂的专利，一种新的治疗治愈乙型肝炎

乙型肝炎病毒（HBV）感染是超过3.5亿人慢性感染全世界，其中的20％至40％处于发展慢性肝病，肝硬化和肝细胞癌的风险是主要的公共卫生问题。尽管有效的预防性疫苗的存在，HBV感染依然猖獗，在许多国家，包括发达国家，每年感染全世界估计有450万新发病例。在开始于2009年和领导Edelris，与其合作伙伴INSERM和Poxel的FUI AAP8成立程序NATHEB的框架，FXR已被确定为HBV和新化合物已发现的治疗靶点，从而导致病毒HBV强烈的抑制作用DNA和病毒抗原生产。

“这个项目证明了Edelris科学家用自己的跟踪验证MEDCHEM和分子模拟的专业知识来进行，再加上经验丰富的合作伙伴INSERM和Poxel，成功研发项目的能力。仪器的启动项目是里昂Biopôle的贡献评论说，“迪迪埃罗氏，Edelris副总裁战略创新和Natheb项目的前负责人。

“当科学和商业利益在公私伙伴关系共享，事情都更快地走向有价值的结果，因为已经在Natheb项目的情况下，补充说：”让 - 伊夫·Ortholand，Edelris的首席执行官。 “我们相信Enyo现在已经完全有能力将这一项目转化为有用的治疗药物。”

INSERM Transfert已被任命为代表各方在Enyo的专利协议。

根据许可协议，Edelris是符合在具体的发展和商业成就的里程碑，并会收到销售特许使用金。

关于Edelris

Edelris是一家私营独资研发和服务公司，提供了筛选化合物和创新的片段为FBDD原始天然产物样的集合（Keymical集合™和片段™），以及高效的命中/铅优化功能。公司自成立以来，Edelris赢得了全球众多客户，并已成功研制出具有大型制药公司，生物技术公司和学术团体，无论是在其内部发现的努力直接支持或合作项目的框架内化学程序。

联系方式：让 - 伊夫·Ortholand
电话：+33（0）4-37-56-19-03
电子邮件：[email protected]
网址：http://www.edelris.com

来源Edelris

作者: styxl 时间: 2015-11-25 17:36

赞一个

作者: jinpaimanman 时间: 2015-11-25 17:47

乙型肝炎病毒（HBV）感染是超过3.5亿人慢性感染全世界，其中的20％至40％处于发展慢性肝病,,看来超过早前官方的25%，，很大的市场

作者: hbv_challenger 时间: 2015-11-29 19:56

具体的成果是什么？能不能简单说明一下

作者: zgct 时间: 2015-11-30 07:36

感谢

作者: StephenW 时间: 2015-11-30 16:45

回复 hbv_challenger 的帖子

我的猜测:
该专利涉及到法尼醇X受体（FXR）。 FXRalpha受体拮抗剂(antagonist)可以抑制HBV的复制

作者: hbv_challenger 时间: 2015-11-30 17:54

本帖最后由 hbv_challenger 于 2015-11-30 17:55 编辑

回复 StephenW 的帖子

那离具体的成果还有很大距离。静待。

作者: StephenW 时间: 2015-11-30 18:00

回复 hbv_challenger 的帖子

很大距离, 没有指定的候选药物.

作者: HBVCURER 时间: 2015-11-30 19:14

Lead compound（先导化合物）已经有了，后续需要做进一步优化。如果进展顺利，离临床阶段大约还有1-2年。FXR可能确实是个不错的药物靶点，就是出来的有点晚。

作者: StephenW 时间: 2015-12-1 03:23

ENYO Pharma Strengthens Its Arsenal of Hepatitis B Potential Therapies
November 30, 2015 09:57 AM Eastern Standard Time

LYON, France--(BUSINESS WIRE)--ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.

This nuclear receptor, also known as a bile acid receptor, acts via several metabolic pathways and in particular by controlling the fate of bile acids in the liver and intestine. It also influences the insulin sensitivity of these tissues where it is highly expressed.

“We are delighted to have obtained access to this patent to use FXR agonists, which is crucial to our future developments in liver infections. It will strengthen the intellectual property portfolio underpinning our flagship hepatitis B program, a condition with tremendous unmet need for new therapies. EYP001, the first product developed under this program, which we licensed from Poxel in early 2015, is nearing the end of its regulatory toxicology trials. Clinical trials are scheduled to begin in early 2016”, commented Jacky Vonderscher, PhD, CEO of ENYO Pharma.

According to the WHO, over 350 million people chronically infected with the hepatitis B virus are awaiting treatment, half them in Asia and chiefly in China. Despite progress with vaccine coverage, close to 300 million people will remain chronically infected in the 2030s, putting them at major risk of developing cirrhosis and liver cancer.

The FXR receptor directly regulates replication of the hepatitis B virus. The dependence of the virus’ life cycle on the bile acids pathway was highlighted by Patrice André and Vincent Lotteau, ENYO Pharma’s founders and Inserm research scientists. Modulating the FXR receptor has thus become a promising new therapeutic avenue for controlling and potentially curing chronic hepatitis B, one of the main causes worldwide of liver cancer and cirrhosis.

The effectiveness of FXR agonists against hepatitis B was discovered and patented by a consortium of these Inserm research scientists and their industry partners Poxel and Edelris. Inserm Transfert was mandated to represent all the parties (Inserm, CNRS, UCBL, ENS-Lyon, Poxel and Elderis) to this patent licensing agreement with ENYO Pharma. This agreement follows on from an initial licensing agreement in May 2015 under which ENYO Pharma acquired Poxel’s rights to a family of FXR agonist compounds for all therapeutic indications, with Poxel retaining a right of first refusal on the cardiovascular and metabolic condition indications.

What sets ENYO Pharma’s approach apart is that it targets the host cellular functions, which are essential for replication of the virus, rather than the constituents of the virus. Viruses have interactions between their own proteins and the host cellular proteins that can hijack human cell mechanisms for their own benefit using highly effective strategies. By blocking these crucial interactions for the virus, this new approach can be used to prevent resistance from arising and diversify the therapeutic arsenal.

ENYO Pharma aims to complete rapidly all the studies required to submit a Clinical Trial Application (CTA) so that it can commence phase I clinical trials of the principal compound in spring 2016 on healthy volunteers and thereby begin treating patients with chronic hepatitis B as part of phase II trials by 2017.

◊◊◊◊

About ENYO Pharma SAS - www.enyopharma.com

Based in Lyon (France), ENYO Pharma was founded in January 2014 by Inserm research scientists to develop treatments for acute and chronic viral infections. Seed funds including Inserm Transfert Initiative, ADV Life Sciences and Vonderscher & Co. were joined in early 2015 by Sofinnova Partners, a venture capital firm based in Paris. ENYO Pharma’s strategy is to disrupt the nexus of interactions between viral proteins and human cellular proteins to prevent the virus from multiplying. ENYO Pharma has thus licensed several Inserm patents originating from discoveries made by the research scientists who founded the company and has developed a unique platform to identify new intracellular therapeutic targets and molecules acting against these targets.

Contacts

Contact ENYO Pharma SAS:
Jacky Vonderscher, Ph.D.
President
[email protected]
or
Press contacts:
NewCap Media
Annie-Florence Loyer, +33 (0)1 44 71 00 12
+33 (0)6 88 20 35 59
[email protected]

作者: StephenW 时间: 2015-12-1 03:25

ENYO制药巩固了其乙肝潜在的治疗阿森纳
二零一五年十一月三十零日上午9点57分东部标准时间

法国里昂 - （美国商业资讯） - ENYO制药公司是一家生物制药公司，致力于开发治疗急性和慢性病毒感染，宣布其已获得的许可证的关键专利，使其能够使用法尼醇X受体激动剂（FXR）乙肝的治疗。

通过多个代谢途径，特别是通过控制胆汁酸在肝脏和小肠的命运这个核受体，也被称为胆汁酸受体，作用。它也影响这些组织在那里高表达的胰岛素敏感性。

“我们已经获得访问该专利使用FXR激动剂，这是非常重要的我们的未来发展肝脏感染高兴。这将加强知识产权组合支撑我们的旗舰乙肝项目，与巨大的未满足的需要新的治疗条件。 EYP001，这个程序，这是我们从Poxel在2015年初许可下开发的第一款产品，已接近其监管毒理学试验结束。临床试验预计于2016年年初“评论说张学友Vonderscher，博士，ENYO制药公司的首席执行官。

根据世界卫生组织，超过350万人感染慢性乙肝病毒正在等待治疗，其中一半在亚洲主要是在中国。尽管与疫苗接种率，接近300万人的进展仍将是慢性感染，在21世纪30年代，这使他们发展为肝硬化和肝癌的主要危险。

该FXR受体直接调节乙肝病毒的复制。病毒的生命周期中的胆汁酸途径的依赖性强调帕特里斯·安德烈和Vincent Lotteau，ENYO制药公司的创始人和INSERM研究的科学家。因此，调节FXR受体已成为一个充满希望的新的治疗途径来控制和潜在的治疗慢性乙型肝炎的主要原因全世界肝癌和肝硬化之一。

FXR激动剂对B型肝炎的有效性被发现，并通过这些INSERM研究的科学家和他们的行业合作伙伴Poxel和Edelris财团专利。 INSERM Transfert的任务是代表所有各方（INSERM，法国国家科学研究中心，UCBL，ENS-里昂，Poxel和Elderis）与ENYO制药这项专利授权协议。该协议是从2015年5月下ENYO制药收购Poxel的权利，一个家庭的FXR激动剂化合物的所有治疗适应症，与Poxel保留对心血管和代谢状态指示优先受让权的初始许可协议。

什么套ENYO制药的做法与众不同的是，它的目标主机细胞的功能，这是必不可少的病毒的复制，而不是病毒的成分。病毒有自己的蛋白质和宿主细胞蛋白，可以劫持人体细胞机制，为自己的利益使用高度有效的策略之间的相互作用。通过阻断该病毒这些重要的相互作用，这种新方法可以用于防止电阻所引起和多样化的治疗武器。

ENYO制药的目的是迅速完成所有需要提交临床试验申请（CTA）的研究，以便它可以开始阶段的主要化合物的I期临床试验在春天2016年的健康志愿者，并由此开始治疗慢性乙型肝炎的一部分II期试验到2017年。

◊◊◊◊

关于ENYO制药SAS - www.enyopharma.com

总部设在法国里昂，ENYO制药成立于2014年1月由INSERM科学家开发用于急，慢性病毒感染的治疗。种子基金，包括INSERM Transfert倡议，ADV生命科学和Vonderscher及公司由Sofinnova Partners总部位于巴黎的一家风险投资公司都参加了2015年年初。 ENYO医药的战略是破坏病毒蛋白和人类细胞蛋白之间的相互作用的关系，以防止病毒的繁殖。 ENYO制药也由此许可数INSERM专利由科学家的研究谁创立了公司，并已形成了独特的平台，以确定新的细胞治疗靶点和分子的行动反对这些目标中发现的始发。

联系方式

联系ENYO制药SAS：
张学友Vonderscher博士
主席
[email protected]
要么
媒体联系方式：
NewCap媒体
安妮 - 佛罗伦萨劳尔，+33（0）1 44 71 00 12
+33（0）6 88 20 35 59
[email protected]

作者: HBVCURER 时间: 2015-12-1 09:21

StephenW 发表于 2015-12-1 03:25
ENYO制药巩固了其乙肝潜在的治疗阿森纳
二零一五年十一月三十零日上午9点57分东部标准时间

看来项目加速了，之前我们内部的预期是2017年内开始一期，这就是资本的力量吧。

当然，“scheduled to begin in early 2016”，这其实是一个很宽泛的界定；从起始招募到“First in Patient”，中间也还有很长的时间要走。

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)